Full Press Release Details
dupixent dupilumab recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis.
REGN
dupixent dupilumab recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis
Key Takeaway: dupixent dupilumab recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis